Cargando…
A reengineered common chain cytokine augments CD8(+) T cell–dependent immunotherapy
Cytokine therapy is limited by undesirable off-target side effects as well as terminal differentiation and exhaustion of chronically stimulated T cells. Here, we describe the signaling properties of a potentially unique cytokine by design, where T cell surface binding and signaling are separated bet...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220948/ https://www.ncbi.nlm.nih.gov/pubmed/35603788 http://dx.doi.org/10.1172/jci.insight.158889 |
_version_ | 1784732501321711616 |
---|---|
author | Banerjee, Anirban Li, Dongge Guo, Yizhan Mei, Zhongcheng Lau, Christine Chen, Kelly Westwick, John Klauda, Jeffery B. Schrum, Adam Lazear, Eric R. Krupnick, Alexander S. |
author_facet | Banerjee, Anirban Li, Dongge Guo, Yizhan Mei, Zhongcheng Lau, Christine Chen, Kelly Westwick, John Klauda, Jeffery B. Schrum, Adam Lazear, Eric R. Krupnick, Alexander S. |
author_sort | Banerjee, Anirban |
collection | PubMed |
description | Cytokine therapy is limited by undesirable off-target side effects as well as terminal differentiation and exhaustion of chronically stimulated T cells. Here, we describe the signaling properties of a potentially unique cytokine by design, where T cell surface binding and signaling are separated between 2 different families of receptors. This fusion protein cytokine, called OMCPmutIL-2, bound with high affinity to the cytotoxic lymphocyte-defining immunoreceptor NKG2D but signaled through the common γ chain cytokine receptor. In addition to precise activation of cytotoxic T cells due to redirected binding, OMCPmutIL-2 resulted in superior activation of both human and murine CD8(+) T cells by improving their survival and memory cell generation and decreasing exhaustion. This functional improvement was the direct result of altered signal transduction based on the reorganization of surface membrane lipid rafts that led to Janus kinase-3–mediated phosphorylation of the T cell receptor rather than STAT/AKT signaling intermediates. This potentially novel signaling pathway increased CD8(+) T cell response to low-affinity antigens, activated nuclear factor of activated T cells transcription factors, and promoted mitochondrial biogenesis. OMCPmutIL-2 thus outperformed other common γ chain cytokines as a catalyst for in vitro CD8(+) T cell expansion and in vivo CD8(+) T cell–based immunotherapy. |
format | Online Article Text |
id | pubmed-9220948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-92209482022-06-24 A reengineered common chain cytokine augments CD8(+) T cell–dependent immunotherapy Banerjee, Anirban Li, Dongge Guo, Yizhan Mei, Zhongcheng Lau, Christine Chen, Kelly Westwick, John Klauda, Jeffery B. Schrum, Adam Lazear, Eric R. Krupnick, Alexander S. JCI Insight Research Article Cytokine therapy is limited by undesirable off-target side effects as well as terminal differentiation and exhaustion of chronically stimulated T cells. Here, we describe the signaling properties of a potentially unique cytokine by design, where T cell surface binding and signaling are separated between 2 different families of receptors. This fusion protein cytokine, called OMCPmutIL-2, bound with high affinity to the cytotoxic lymphocyte-defining immunoreceptor NKG2D but signaled through the common γ chain cytokine receptor. In addition to precise activation of cytotoxic T cells due to redirected binding, OMCPmutIL-2 resulted in superior activation of both human and murine CD8(+) T cells by improving their survival and memory cell generation and decreasing exhaustion. This functional improvement was the direct result of altered signal transduction based on the reorganization of surface membrane lipid rafts that led to Janus kinase-3–mediated phosphorylation of the T cell receptor rather than STAT/AKT signaling intermediates. This potentially novel signaling pathway increased CD8(+) T cell response to low-affinity antigens, activated nuclear factor of activated T cells transcription factors, and promoted mitochondrial biogenesis. OMCPmutIL-2 thus outperformed other common γ chain cytokines as a catalyst for in vitro CD8(+) T cell expansion and in vivo CD8(+) T cell–based immunotherapy. American Society for Clinical Investigation 2022-05-23 /pmc/articles/PMC9220948/ /pubmed/35603788 http://dx.doi.org/10.1172/jci.insight.158889 Text en © 2022 Banerjee et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Banerjee, Anirban Li, Dongge Guo, Yizhan Mei, Zhongcheng Lau, Christine Chen, Kelly Westwick, John Klauda, Jeffery B. Schrum, Adam Lazear, Eric R. Krupnick, Alexander S. A reengineered common chain cytokine augments CD8(+) T cell–dependent immunotherapy |
title | A reengineered common chain cytokine augments CD8(+) T cell–dependent immunotherapy |
title_full | A reengineered common chain cytokine augments CD8(+) T cell–dependent immunotherapy |
title_fullStr | A reengineered common chain cytokine augments CD8(+) T cell–dependent immunotherapy |
title_full_unstemmed | A reengineered common chain cytokine augments CD8(+) T cell–dependent immunotherapy |
title_short | A reengineered common chain cytokine augments CD8(+) T cell–dependent immunotherapy |
title_sort | reengineered common chain cytokine augments cd8(+) t cell–dependent immunotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220948/ https://www.ncbi.nlm.nih.gov/pubmed/35603788 http://dx.doi.org/10.1172/jci.insight.158889 |
work_keys_str_mv | AT banerjeeanirban areengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT lidongge areengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT guoyizhan areengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT meizhongcheng areengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT lauchristine areengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT chenkelly areengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT westwickjohn areengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT klaudajefferyb areengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT schrumadam areengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT lazearericr areengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT krupnickalexanders areengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT banerjeeanirban reengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT lidongge reengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT guoyizhan reengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT meizhongcheng reengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT lauchristine reengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT chenkelly reengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT westwickjohn reengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT klaudajefferyb reengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT schrumadam reengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT lazearericr reengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy AT krupnickalexanders reengineeredcommonchaincytokineaugmentscd8tcelldependentimmunotherapy |